# Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission

> **NCT00939068** · PHASE4 · UNKNOWN · sponsor: **Southeast University, China** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Hepatitis B, Gestation

## Interventions

- **DRUG:** Telbivudine
- **BIOLOGICAL:** engineered HB vaccine

## Key facts

- **NCT ID:** NCT00939068
- **Lead sponsor:** Southeast University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2009-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939068, "Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00939068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*